Robbins R J, Kern P A, Thompson T L
Am J Med. 1984 May;76(5):921-3. doi: 10.1016/0002-9343(84)91010-6.
Reported herein is the possible interaction between two drugs used to treat a man with a large prolactin-secreting pituitary adenoma. The patient had a long history of schizophrenia that was treated with many different medications, including phenothiazines. Evaluation of progressive lethargy led to the discovery of a large parasellar tumor and a prolactin level of 7,981 ng/ml. His serum prolactin level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. A marked deterioration of his visual fields was noted after 3 months' therapy with both drugs, and this abnormality resolved five days after the thioridazine was stopped. The use of dopamine antagonists such as thioridazine in patients with prolactinoma may interfere with bromocriptine's action, resulting in potentially serious complications.
本文报道了用于治疗一名患有大泌乳素分泌型垂体腺瘤男性患者的两种药物之间可能存在的相互作用。该患者有长期精神分裂症病史,曾使用多种不同药物治疗,包括吩噻嗪类药物。渐进性嗜睡的评估导致发现一个鞍旁大肿瘤,泌乳素水平为7981 ng/ml。在溴隐亭治疗期间,他的血清泌乳素水平降至400 ng/ml范围,但每当将抗精神病药物硫利达嗪添加到他的治疗方案中时,泌乳素水平就会升高。两种药物联合治疗3个月后,发现其视野明显恶化,停用硫利达嗪5天后,这种异常情况得到缓解。在泌乳素瘤患者中使用硫利达嗪等多巴胺拮抗剂可能会干扰溴隐亭的作用,从而导致潜在的严重并发症。